Livid over Lipids No Longer; Alnylam, Tekmira Find Peace
By Randy Osborne
Wednesday, November 14, 2012
Alnylam Pharmaceuticals Inc.'s eleventh-hour settlement with Tekmira Pharmaceuticals Corp. leaves Alnylam $65 million lighter but still in strong financial shape, without losing rights to access the Lipid NanoParticle (LNP) delivery technology important for its RNAi work.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.